Ginkgo Bioworks Holdings (DNA) Accumulated Expenses (2020 - 2026)

Ginkgo Bioworks Holdings has reported Accumulated Expenses for 7 years, with the latest figure at $48.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 31.62% year-over-year to $48.4 million; the trailing twelve-month figure through Mar 2026 stood at $48.4 million (down 31.62% YoY), and the FY2025 full-year result was $66.5 million, up 1.64% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $48.4 million, down from $66.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $122.6 million in Q1 2023, with the low at $48.4 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $87.9 million across 5 years, with a median of $79.3 million in 2025.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 57.69% — and 2025, when it plunged 51.13%.
• Ginkgo Bioworks Holdings' Accumulated Expenses stood at $114.7 million in 2022, then fell by 4.05% to $110.1 million in 2023, then plunged by 40.58% to $65.4 million in 2024, then advanced by 1.64% to $66.5 million in 2025, then slipped by 27.21% to $48.4 million in 2026.
• The last three Accumulated Expenses figures came in at $48.4 million (Q1 2026), $66.5 million (Q4 2025), and $79.3 million (Q3 2025), per Business Quant data.